2012-09-18 08:10:32 - Recently published research from Global Markets Direct, "Cutaneous Lupus Erythematosus - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Cutaneous Lupus Erythematosus - Pipeline Review, H2 2012', provides an overview of the Cutaneous Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous Lupus Erythematosus. 'Cutaneous Lupus Erythematosus - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and

relevance of data for the indicated disease.


Full Report Details at
- www.fastmr.com/prod/463805_cutaneous_lupus_erythematosus_pipelin ..


Scope

* A snapshot of the global therapeutic scenario for Cutaneous Lupus Erythematosus.
* A review of the Cutaneous Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Cutaneous Lupus Erythematosus pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Cutaneous Lupus Erythematosus.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Cutaneous Lupus Erythematosus pipeline depth and focus of Cutaneous Lupus Erythematosus therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Cutaneous Lupus Erythematosus Therapeutic Products under Development, Key Players in Cutaneous Lupus Erythematosus Therapeutics, Cutaneous Lupus Erythematosus Pipeline Overview, Cutaneous Lupus Erythematosus Pipeline, Cutaneous Lupus Erythematosus Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cutaneous Lupus Erythematosus Overview
Therapeutics Development
An Overview of Pipeline Products for Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Cutaneous Lupus Erythematosus Therapeutics - Products under Development by Companies
Companies Involved in Cutaneous Lupus Erythematosus Therapeutics Development
Amgen Inc.
Rigel Pharmaceuticals, Inc.
Celgene Corporation
Tolerx, Inc.
Cutaneous Lupus Erythematosus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMG 811 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG 557 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNK CC-930 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-11050 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRX1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-333 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cutaneous Lupus Erythematosus Therapeutics - Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Cutaneous Lupus Erythematosus, H2 2012
Products under Development for Cutaneous Lupus Erythematosus - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Amgen Inc., H2 2012
Rigel Pharmaceuticals, Inc., H2 2012
Celgene Corporation, H2 2012
Tolerx, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463805&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.